TNF Pharmaceuticals, Inc. Common StockTNFA
Market Cap: $2.87M
About: TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.
Employees: 6
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
5% more funds holding
Funds holding: 20 [Q1] → 21 (+1) [Q2]
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
92% less capital invested
Capital invested by funds: $1.38M [Q1] → $115K (-$1.26M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for TNFA.